Médicaments SGLT2i et AR GLP-1 recommandés par les directives pour les patients présentant un DT2 et une ASCVD comorbides

Date de début de l'étude : 18 août 2021

Inclusion Criteria: Patient * Patients with T2DM defined as ≥2 outpatient diagnoses of T2DM in any position on separate days; OR ≥1 inpatient diagnosis T2DM in any position; OR ≥1 outpatient diagnosis in any position AND ≥1 medication claim for T2DM * ≥1 diagnosis code for ASCVD (coronary artery disease diagnoses or procedures, cerebrovascular disease, peripheral artery disease of atherosclerotic origin) on any claim type in any position within the 24-month period prior to identification * Enrolled in a Humana Medicare Advantage Prescription Drug plan with ≥12 months pre-identification continuous enrollment (no more than a 31 day gap) as of the identification date and currently enrolled as of the identification date * Age 18-85 years at time of identification * Patients residing in Kentucky (KY), West Virginia (WV), Pennsylvania (PA), and 6 counties in south New Jersey (NJ) (Burlington, Camden, Cumberland, Gloucester, Mercer, Salem) (United States) Provider * Primary care providers of the identified patients Exclusion Criteria: Patients * ≥1 diagnosis or procedure code for end-stage kidney disease, renal transplant, dialysis or kidney failure * Any hospice or long-term care residence * ≥1 code for pregnancy/childbirth * Patients with any use of SGLT2i or GLP-1 RA medications in the pre-identification period * Patients without an attributed primary care provider * Patients on do not contact lists * Patients without valid addresses and telephone numbers * Patients with ≥1 diagnosis for type 1 diabetes pre-identification Primary care providers * Providers on do not contact lists * Providers without valid fax/mailing address and phone number * Providers with \<3 or \>50 eligible patients